# 35 - 273 Aortic Regurgitation

### 273 Aortic Regurgitation

Patrick T. O’Gara, Joseph Loscalzo

Aortic Regurgitation
■
■ETIOLOGY
(Table 273-1) Aortic regurgitation (AR) may be caused by primary 
valve disease, aortic root disease, or their combination.
Primary Valve Disease 
Rheumatic disease results in thicken­
ing, deformity, and shortening of the individual aortic valve cusps, 
changes that prevent their proper opening during systole and closure 
during diastole. A rheumatic origin is much less common in patients 
with isolated AR who do not have associated rheumatic mitral valve 
disease. Patients with congenital bicuspid aortic valve (BAV) disease 
may develop predominant AR, and ~20% of these patients will require 
aortic valve surgery between 10 and 40 years of age. Congenital fenes­
trations of the aortic valve occasionally produce mild AR. Membranous 
subaortic stenosis results in a high-velocity systolic jet that often leads 
to thickening and scarring of the aortic valve leaflets and secondary 
AR. Prolapse of an aortic cusp, resulting in progressive chronic AR, 
occurs in ~15% of patients with ventricular septal defect (Chap. 280), 
but may also occur as an isolated phenomenon or as a consequence of 
myxomatous degeneration sometimes associated with mitral and/or 
tricuspid valve involvement.
AR may result from infective endocarditis (IE), which can develop 
on a valve previously affected by rheumatic disease, a congenitally 
deformed valve, or on a normal aortic valve, and may lead to perfora­
tion or destruction of one or more leaflets. The aortic valve leaflets may 
become scarred and retracted during the course of syphilis or ankylos­
ing spondylitis and contribute further to the AR that derives primarily 
from associated root dilation. Although traumatic rupture or avulsion 
of an aortic cusp is an uncommon cause of acute AR, it represents 
the most frequent serious lesion in patients surviving nonpenetrat­
ing cardiac injuries. The coexistence of hemodynamically significant 
aortic stenosis (AS) with AR usually excludes all the rarer forms of 
AR because it occurs almost exclusively in patients with rheumatic or 
congenital AR. In patients with AR due to primary valvular disease, 
dilation of the aortic annulus may occur secondarily and lead to wors­
ening regurgitation.
Primary Aortic Root Disease 
AR also may be due entirely to 
marked aortic annular dilation, i.e., aortic root disease, without pri­
mary involvement of the valve leaflets; widening of the aortic annulus 
and lack of diastolic coaptation of the aortic leaflets are responsible 
for the AR (Chap. 291). Medial degeneration of the ascending aorta, 
TABLE 273-1  Major Causes of Aortic Regurgitation
VALVE LESION
ETIOLOGIES
Aortic regurgitation
Valvular
  Congenital (bicuspid)
  Endocarditis
  Rheumatic fever
  Myxomatous (prolapse)
  Radiation
  Trauma
  Syphilis
  Ankylosing spondylitis
Aortic root disease
  Aortic dissection
  Medial degeneration
  Marfan syndrome
  Bicuspid aortic valve
  Nonsyndromic familial aneurysm
  Aortitis
  Hypertension

which may or may not be associated with other manifestations of 
Marfan’s syndrome; idiopathic dilation of the aorta; annuloaortic 
ectasia; osteogenesis imperfecta; and severe, chronic hypertension may 
all widen the aortic annulus and lead to progressive AR. Occasionally 
AR is caused by retrograde dissection of the aorta involving the aortic 
annulus. Syphilis and ankylosing spondylitis, both of which may also 
affect the aortic leaflets, may be associated with cellular infiltration and 
scarring of the media of the thoracic aorta, leading to aortic dilation, 
aneurysm formation, and severe regurgitation. In syphilis of the aorta 
(Chap. 187), now a very rare condition, the involvement of the intima 
may narrow the coronary ostia, which in turn may be responsible for 
myocardial ischemia. Takayasu’s aortitis and giant cell aortitis can also 
result in aneurysm formation and secondary AR.

CHAPTER 273
Aortic Regurgitation
■
■PATHOPHYSIOLOGY
The total stroke volume ejected by the left ventricle (LV) (i.e., the sum 
of the effective forward stroke volume and the volume of blood that 
regurgitates back into the LV) is increased in patients with AR. In 
patients with severe AR, the volume of regurgitant flow may equal the 
effective forward stroke volume. In contrast to MR, in which a portion 
of the LV stroke volume is delivered into the low-pressure left atrium 
(LA), in AR, the entire LV stroke volume is ejected into a high-pressure 
zone, the aorta. An increase in the LV end-diastolic volume (increased 
preload) constitutes the major hemodynamic compensation for AR. 
The dilation and eccentric hypertrophy of the LV allow this chamber 
to eject a larger stroke volume without requiring any increase in the 
relative shortening of each myofibril. Therefore, severe AR may occur 
with a normal effective forward stroke volume and a normal LV ejec­
tion fraction (LVEF, total [forward plus regurgitant] stroke volume/
end-diastolic volume), together with an elevated LV end-diastolic 
pressure and volume. However, through the operation of Laplace’s law, 
LV dilation increases the LV systolic tension required to develop any 
given level of systolic pressure. Chronic AR is, thus, a state in which 
LV preload and afterload are both increased. Ultimately, these adaptive 
measures fail. As LV function deteriorates, the end-diastolic volume 
rises further and the forward stroke volume and ejection fraction (EF) 
decline. Deterioration of LV function often precedes the development 
of symptoms. Considerable thickening of the LV wall also occurs with 
chronic AR, and at autopsy, the hearts of these patients may be among 
the largest encountered, sometimes weighing >1000 g.
The reverse diastolic pressure gradient from aorta to LV, which drives 
the AR flow, decreases progressively during diastole, accounting for 
the typical decrescendo nature of the diastolic murmur. Equilibration 
between aortic and LV pressures may occur toward the end of diastole in 
patients with chronic severe AR, particularly when the heart rate is slow. 
In patients with acute severe AR, the LV is unprepared for the regurgi­
tant volume load. LV compliance is normal or reduced, and LV diastolic 
pressures rise rapidly, occasionally to levels >40 mmHg. The LV pressure 
may exceed the LA pressure toward the end of diastole, and this reversed 
pressure gradient closes the mitral valve prematurely.
In patients with chronic severe AR, the effective forward cardiac 
output (CO) usually is normal or only slightly reduced at rest, but often 
it fails to rise normally during exercise. An early sign of LV dysfunction 
is a reduction in the EF. In advanced stages, there may be considerable 
elevation of the LA, pulmonary artery (PA) wedge, PA, and right ven­
tricular (RV) pressures and reduced forward CO at rest.
Myocardial ischemia may occur in patients with AR because myo­
cardial oxygen requirements are elevated by LV dilation, hypertrophy, 
and elevated LV systolic tension, and coronary blood flow may be 
compromised. A large fraction (the majority) of coronary blood flow 
occurs during diastole, when aortic pressure is low, thereby reducing 
coronary perfusion or driving pressure. This combination of increased 
oxygen demand and reduced supply may cause myocardial ischemia, 
particularly of the subendocardium, even in the absence of epicardial 
coronary artery disease (CAD).
■
■HISTORY
Approximately three-fourths of patients with pure or predominant val­
vular AR are men; women predominate among patients with primary

valvular AR who have associated rheumatic mitral valve disease. A his­
tory compatible with IE may sometimes be elicited from patients with 
rheumatic or congenital involvement of the aortic valve, and the infec­
tion often precipitates or seriously aggravates preexisting symptoms.

In patients with acute severe AR, as may occur in IE, aortic dissec­
tion, or trauma, the LV cannot dilate sufficiently to maintain stroke 
volume, and LV diastolic pressure rises rapidly with associated marked 
elevations of LA and PA wedge pressures. Pulmonary edema and/or 
cardiogenic shock may develop rapidly.
PART 6
Disorders of the Cardiovascular System
Chronic severe AR may have a long latent period, and patients may 
remain relatively asymptomatic for as long as 10–15 years. Uncomfort­
able awareness of the heartbeat, especially on lying down, may be an 
early complaint. Sinus tachycardia, during exertion or with emotion, or 
premature ventricular contractions may produce particularly uncom­
fortable palpitations as well as head pounding. These complaints may 
persist for many years before the development of exertional dyspnea, 
usually the first symptom of diminished cardiac reserve. The dyspnea 
is followed by orthopnea, paroxysmal nocturnal dyspnea, and excessive 
diaphoresis. Anginal chest pain even in the absence of CAD may occur 
in patients with severe AR, even in younger patients. Anginal pain may 
develop at rest as well as during exertion. Nocturnal angina may be 
a particularly troublesome symptom, and it may be accompanied by 
marked diaphoresis. The anginal episodes can be prolonged and often 
do not respond satisfactorily to sublingual nitroglycerin. Systemic fluid 
accumulation, including congestive hepatomegaly and ankle edema, 
may develop late in the course of the disease.
■
■PHYSICAL FINDINGS
In chronic severe AR, the jarring of the entire body and the bobbing 
motion of the head with each systole can be appreciated, and the abrupt 
distention and collapse of the larger arteries are easily visible. The 
examination should be directed toward the detection of conditions 
predisposing to AR, such as bicuspid valve, IE, Marfan’s syndrome, or 
ankylosing spondylitis.
Arterial Pulse 
A rapidly rising “water-hammer” pulse, which col­
lapses suddenly as arterial pressure falls rapidly during late systole and 
diastole (Corrigan’s pulse), and capillary pulsations, an alternate flushing 
and paling of the skin at the root of the nail while pressure is applied to 
the tip of the nail (Quincke’s pulse), are characteristic of chronic severe 
AR. A booming “pistol-shot” sound can be heard over the femoral arter­
ies (Traube’s sign), and a to-and-fro murmur (Duroziez’s sign) is audible 
if the femoral artery is lightly compressed with a stethoscope.
The arterial pulse pressure is widened as a result of both systolic 
hypertension and a lowering of the diastolic pressure. The measure­
ment of arterial diastolic pressure with a sphygmomanometer may be 
complicated by the fact that systolic sounds are frequently heard with 
the cuff completely deflated. However, the level of cuff pressure at the 
time of muffling of the Korotkoff sounds (phase IV) generally corre­
sponds fairly closely to the true intra-arterial diastolic pressure. As the 
disease progresses and the LV end-diastolic pressure rises, the arterial 
diastolic pressure may actually rise as well, because the aortic diastolic 
pressure cannot fall below the LV end-diastolic pressure. For the same 
reason, acute severe AR may also be accompanied by only a slight wid­
ening of the pulse pressure. Such patients are invariably tachycardic as 
the heart rate increases in an attempt to preserve the CO.
Palpation 
In patients with chronic severe AR, the LV impulse is 
heaving and displaced laterally and inferiorly. The systolic expansion 
and diastolic retraction of the apex are prominent. A diastolic thrill 
may be palpable along the left sternal border in thin-chested individu­
als, and a prominent systolic thrill may be palpable in the suprasternal 
notch and transmitted upward along the carotid arteries. This systolic 
thrill and the accompanying murmur do not necessarily signify the 
coexistence of AS. In some patients with AR or with combined AS and 
AR, the carotid arterial pulse may be bisferiens, i.e., with two systolic 
waves separated by a trough (see Fig. 246-2C).
Auscultation 
In patients with severe AR, the aortic valve closure 
sound (A2) is usually absent. A systolic ejection sound is audible in 

patients with BAV disease, and occasionally an S4 also may be heard. 
The murmur of chronic AR is typically a high-pitched, blowing, decre­
scendo diastolic murmur, heard best in the third intercostal space along 
the left sternal border (see Fig. 246-5B). In patients with mild AR, this 
murmur is brief, but as the severity increases, it generally becomes 
louder and longer, indeed holodiastolic. When the murmur is soft, it 
can be heard best with the diaphragm of the stethoscope and with the 
patient sitting up, leaning forward, and with the breath held in forced 
expiration. In patients in whom the AR is caused by primary valvular 
disease, the diastolic murmur is usually louder along the left than the 
right sternal border. However, when the murmur is louder along the 
right sternal border, it suggests that the AR is caused by aneurysmal 
dilation of the aortic root. “Cooing” or musical diastolic murmurs 
suggest eversion of an aortic cusp vibrating in the regurgitant stream.
A mid-systolic ejection murmur is frequently audible in isolated 
AR. It is generally heard best at the base of the heart and is transmitted 
along the carotid arteries. This murmur may be quite loud without sig­
nifying aortic valve obstruction. A third murmur sometimes heard in 
patients with severe AR is the Austin Flint murmur, a soft, low-pitched, 
rumbling mid-to-late diastolic murmur. It is probably produced by the 
diastolic displacement of the anterior leaflet of the mitral valve by the 
AR stream and is not associated with hemodynamically significant 
mitral valve obstruction. The auscultatory features of AR are intensi­
fied by strenuous and sustained handgrip, which augments systemic 
vascular resistance and increases LV afterload.
In acute severe AR, the elevation of LV end-diastolic pressure may 
lead to early closure of the mitral valve, a soft S1, a pulse pressure that 
is not particularly wide, and a soft, short, early diastolic murmur of AR.
■
■LABORATORY EXAMINATION
ECG 
In patients with chronic severe AR, ECG signs of LV hyper­
trophy are common (Chap. 247). In addition, these patients frequently 
exhibit ST-segment depression and T-wave inversion in leads I, aVL, 
V5, and V6 (“LV strain”). Left axis deviation and/or QRS prolongation 
may also be present.
Echocardiogram (Fig. 273-1) 
LV size is increased in chronic 
AR, and systolic function is normal or even supernormal until myocar­
dial contractility declines, as signaled by a decrease in EF or increase in 
the end-systolic dimension. A rapid, high-frequency diastolic fluttering 
of the anterior mitral leaflet produced by the impact of the regurgi­
tant jet is a characteristic finding. The echocardiogram is also useful 
in determining the cause of AR, by detecting dilation of the aortic 
annulus and root, aortic dissection or primary leaflet pathology. With 
severe AR, the central jet width assessed by color flow Doppler imag­
ing exceeds 65% of the width of the LV outflow tract, the regurgitant 
volume is ≥60 mL/beat, the regurgitant fraction is ≥50%, and there is 
diastolic flow reversal in the proximal portion of the descending tho­
racic aorta. The continuous-wave Doppler profile of the AR jet shows 
a rapid deceleration time in patients with acute severe AR, due to the 
rapid increase in LV diastolic pressure. Surveillance transthoracic 
echocardiography (TTE) forms the cornerstone of longitudinal followup and allows for the early detection of changes in LV size and/or 
function. Assessment of LV global longitudinal strain (GLS; a measure 
of myocardial thickening in systole) with speckle track imaging may 
demonstrate changes in LV systolic function that precede a fall in EF. 
There is increasing experience with the use of three-dimensional echo­
cardiography to measure LV volumes. Transesophageal echocardiogra­
phy (TEE) can provide detailed anatomic assessment of the valve, root, 
and portions of the aorta. For patients in whom TTE is limited by poor 
acoustical windows or inadequate characterization of LV function or 
the cause or severity of the regurgitation, cardiac magnetic resonance 
(CMR) imaging can be performed. This modality also allows for accu­
rate assessment of LV volumes, as well as aortic size and contour. It 
can also be utilized to screen for increased LV interstitial (extracellular 
volume fraction) and replacement fibrosis (late gadolinium enhance­
ment). Both CMR imaging and cardiac computed tomography (CT) 
can also provide detailed assessment of aortic valve, root, and thoracic 
aortic anatomy.

A
B
FIGURE 273-1  Echocardiographic and Doppler depiction of severe aortic regurgitation. (A) Color flow transesophageal echocardiographic long axis image in diastole 
shows a broad jet of severe aortic regurgitation (AR, yellow arrow) directed into the left ventricle. ECG rhythm strip below. Ao, aorta; BPM, beats per minute; HR, heart rate; 
LV, left ventricle. (B) Continuous wave Doppler tracing (middle image) obtained from the suprasternal window (top image) during transthoracic echocardiography shows 
dense, holodiastolic flow reversal in the descending thoracic aorta (yellow arrow) indicative of severe AR. ECG rhythm strip below.
Chest X-Ray 
In chronic severe AR, the apex is displaced down­
ward and to the left in the frontal projection. In the left anterior 
oblique and lateral projections, the LV is displaced posteriorly and 
encroaches on the spine. When AR is caused by primary disease of 
the aortic root, aneurysmal dilation of the aorta may be noted, and 
the aorta may fill the retrosternal space in the lateral view. Echocar­
diography, CMR imaging, and chest CT angiography are more sensi­
tive than a chest x-ray for the detection of root and ascending aortic 
enlargement.
Cardiac Catheterization and Angiography 
When needed, 
right and left heart catheterization with contrast aortography can pro­
vide confirmation of the magnitude of regurgitation and the status of 
LV function. Coronary angiography is performed routinely in patients 
at risk of coronary artery disease prior to surgery, although this ana­
tomic information can also be obtained in many patients with coronary 
CT angiography.
TREATMENT
Aortic Regurgitation
ACUTE AORTIC REGURGITATION (FIG. 273-2)
Patients with acute severe AR may respond to intravenous diuretics 
and vasodilators (such as sodium nitroprusside), but stabilization is 
usually short-lived and operation is indicated urgently. Intra-aortic 
balloon counterpulsation is contraindicated. Beta blockers are best 
avoided so as not to reduce the CO further or slow the heart rate, 
thus allowing more time for diastolic filling of the LV. Surgery is the 
treatment of choice and is usually necessary within 24 h of diagnosis.
CHRONIC AORTIC REGURGITATION
The onset of symptoms, or LV systolic dysfunction, is an indica­
tion for surgery. Medical treatment with diuretics and vasodilators 
(angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers [ARBs], dihydropyridine calcium channel blockers, or 
hydralazine) may be useful as a temporizing measure. Surgery 

CHAPTER 273
Aortic Regurgitation
can then be performed in a more controlled setting. The use of 
vasodilators to extend the compensated phase of chronic severe 
AR in asymptomatic patients before the onset of symptoms or the 
development of LV dysfunction is not useful, although these agents 
should be employed to treat hypertension (systolic blood pressure 
>140 mmHg). It is often difficult to achieve adequate blood pres­
sure control because of the increased stroke volume and enhanced 
LV ejection that accompany severe AR. Cardiac arrhythmias and 
systemic infections are poorly tolerated in patients with severe AR 
and must be treated promptly and vigorously. Although nitroglyc­
erin and long-acting nitrates are not as helpful in relieving anginal 
pain as they are in patients with coronary heart disease, they are 
worth a trial. Patients with syphilitic aortitis should receive a full 
course of penicillin therapy (Chap. 187). Beta blockers and the 
ARB losartan may be useful to retard the rate of aortic root enlarge­
ment in young patients with Marfan’s syndrome and aortic root 
dilation. A randomized controlled trial showed no difference in 
efficacy between atenolol and losartan for this indication. Whether 
beta blockers or ARBs are useful in retarding the rate of growth of 
aortic aneurysms in other patient subsets (e.g., BAV disease with 
aortopathy, Takayasu’s disease) has not been demonstrated. Beta 
blockers in patients with valvular AR were previously considered 
relatively contraindicated due to concern that slowing of the heart 
rate would allow more time for diastolic regurgitation and LV filling. 
Observational reports, however, have suggested that beta blockers 
may provide functional benefit in some patients with chronic AR. 
Beta blockers can sometimes provide incremental blood pressure 
lowering in patients with chronic AR and hypertension. They can 
also lessen the sense of forceful heart action that many patients find 
uncomfortable. Patients with severe AR, particularly those with an 
associated aortopathy, should avoid isometric exercises.
SURGICAL TREATMENT
In deciding on the advisability and proper timing of surgical treat­
ment, two points should be kept in mind: (1) patients with chronic 
severe AR usually do not become symptomatic until after the devel­
opment of myocardial dysfunction; and (2) when delayed too long

PART 6
Disorders of the Cardiovascular System
Severe AR
(VC >0.6 cm, holodiastolic
aortic flow reversal, RVol ≥60 mL,
RF ≥50%, ERO ≥0.3 cm2)
Symptomatic
(Stage D)
Asymptomatic
(Stage C)
Other
cardiac
surgery
EF ≤55%
(Stage C2)
EF ≥55%
LVESD >50 mm
and
LVESD >25 mm/m2
AVR (1)
AVR (2a)
AVR (2a)
AVR (2b)
FIGURE 273-2  Management of patients with aortic regurgitation. See legend for Fig. 272-4 for explanation of treatment recommendations (Class I, IIa, and IIb) and 
disease stages (B, C1, C2, and D). Preoperative coronary angiography should be performed routinely as determined by age, symptoms, and coronary risk factors. Cardiac 
catheterization and angiography may also be helpful when there is a discrepancy between clinical and noninvasive findings. Surgery is indicated for patients with severe 
AR and symptoms, LV dysfunction, or other indications for operation (e.g., aneurysm disease). Surgery is also reasonable once the LV indexed end-systolic dimension 
reaches or exceeds 25 mm/m2. Patients who do not meet criteria for intervention should be monitored periodically with clinical and echocardiographic follow-up. AR, 
aortic regurgitation; AVR, aortic valve replacement (valve repair may be appropriate in selected patients); EDD, end-diastolic dimension; EF, ejection fraction; ERO, effective 
regurgitant orifice; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; 
RF, regurgitant fraction; RVol, regurgitant volume; VC, vena contracta. (Reproduced with permission from CM Otto et al: 2020 AHA/ACC Guideline for management of patients 
with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2021;143(5):e72.)
(defined as >1 year from onset of symptoms or LV dysfunction), 
surgical treatment often does not restore normal LV size and func­
tion. Therefore, in patients with chronic severe AR, careful clinical 
follow-up and noninvasive testing with echocardiography at ~6- to 
12-month intervals are necessary if operation is to be undertaken 
at the optimal time, i.e., coincident with or after the onset of LV 
dysfunction but prior to the development of symptoms. Exercise 
testing may be helpful to assess effort tolerance more objectively 
and should be employed whenever questions about symptoms 
arise. Operation can be deferred as long as the patient both remains 
asymptomatic and retains normal LV function without severe or 
progressive chamber dilation.
Aortic valve replacement (AVR) is indicated for the treatment 
of severe AR in symptomatic patients irrespective of LV function. 
In general, the operation should be carried out in asymptomatic 
patients with severe AR and progressive LV dysfunction defined by 
an LVEF <55% on serial studies, an LV end-systolic dimension 
>50 mm (>25 mm/m2), or an LV diastolic dimension >65 mm. Smaller 
dimensions may be appropriate thresholds in individuals of smaller 
stature or when there is evidence of progressively decreasing LV 
function or increasing LV size on serial studies and the anticipated 
risks for surgical morbidity and mortality are low. Two case series 

Aortic regurgitation
Moderate
AR
Other
cardiac
surgery
Progressive
changes
(≥3 studies)
EF 55–60%
EDD >65 mm
Low
surgical risk
from surgical referral centers have suggested that surgery should 
be performed at an even lower threshold for LV end-systolic 
dimension index (≥20 mm/m2), but data from randomized con­
trolled trials are lacking. Abnormal LV GLS (≥ –18%) has been 
associated with an excess hazard for death in single-center studies. 
Observational studies using either three-dimensional echocar­
diography or CMR imaging have also suggested that event-free 
survival is reduced in asymptomatic patients with an LV endsystolic volume index ≥45 mL/m2, compared with patients with an 
LV end-systolic volume index <45 mL/m2. Patients with severe AR 
without indications for operation should be followed by clinical 
and echocardiographic examination every 6–12 months. Trans­
catheter aortic valve implantation (TAVI) is not recommended 
for patients with severe AR who are surgical candidates. Technical 
success with TAVI in patients with chronic AR is limited by the 
degree of aortic annular dilation and the relative paucity of valvu­
lar and annular calcium.
Surgical options for management of aortic valve and root disease 
have expanded considerably over the past decade. AVR with a suit­
able mechanical or tissue (biological) prosthesis is generally necessary 
in patients with rheumatic AR and in many patients with other causes 
of valvular AR. Rarely, when a leaflet has been perforated during IE

B
A
D
FIGURE 273-3  Valve-sparing aortic root reconstruction (David procedure). Aortic root and proximal ascending aorta (A) are resected (B) with sinuses of Valsalva and 
mobilized coronary artery buttons remaining. Subannular sutures (C) are placed, commissural posts are drawn up inside the valve, and the annular sutures are passed 
through the proximal end of the graft. The annular sutures are tied (D), the valve is reimplanted inside the graft, aortic continuity is reestablished with another graft of 
appropriate size, and the coronary buttons are attached to the side of the graft. (From P Steltzer et al [eds]: Valvular Heart Disease: A Companion to Braunwald’s Heart 
Disease, 3rd ed, Fig. 12-27, p. 200.)
or torn from its attachments to the aortic annulus by thoracic trauma, 
primary surgical repair may be possible. When AR is due to aneurys­
mal dilation of the root or proximal ascending aorta rather than to 
primary valve involvement, it may be possible to reduce or eliminate 
the regurgitation by narrowing the annulus or by excising a portion 
of the aortic root without replacing the valve. Elective, valve-sparing 
aortic root reconstruction generally involves reimplantation of the 
valve in a contoured graft with reattachment of the coronary artery 
buttons into the side of the graft and is best undertaken in specialized 
surgical centers by experienced operators (Fig. 273-3). Resuspension 
of the native aortic valve leaflets is possible in ~50% of patients with 
acute AR in the setting of type A aortic dissection. In other condi­
tions, however, AR can be effectively eliminated only by replacing 
the aortic valve, as well as the dilated or aneurysmal ascending aorta 
responsible for the regurgitation, often using a composite prosthetic 
valve-graft conduit. Pure AR is not by itself a contraindication to the 
Ross procedure, although the presence of aortic annular dilation and/
or an associated aortopathy would eliminate this option.
As is true in patients with other valvular heart disease, both 
operative and late mortality risks are largely dependent on the stage 
of the disease and myocardial function at the time of operation. The 
overall operative mortality rate for isolated AVR performed for pure 
AR is ~1–2%. The mortality risk doubles when aortic surgery is 
added to the operation. Patients with AR, marked cardiac enlarge­
ment, and established LV dysfunction experience an operative 
mortality rate of ~5–10% and a late mortality rate of ~3–5% per 

CHAPTER 273
Aortic Regurgitation
C
year due to LV failure despite a technically satisfactory operation. 
Nonetheless, because of the very poor prognosis with medical 
management, even patients with advanced LV systolic dysfunction 
should be considered for operation.
Patients with acute severe AR require prompt (24–48 h) surgical 
treatment, which may be lifesaving.
■
■FURTHER READING
Hashimoto G et al: Association of left ventricular remodeling assess­
ment by cardiac magnetic resonance with outcomes in patients with 
chronic aortic regurgitation. JAMA Cardiol 7:924, 2022.
Lacro RV et al: Atenolol versus losartan in children and young adults 
with Marfan’s syndrome. N Engl J Med 371:2061, 2014.
Malaisrie SC, McCarthy PM: Surgical approach to disease of the 
aortic valve and the aortic root, in Valvular Heart Disease: A Compan­
ion to Braunwald’s Heart Disease, 5th ed. CM Otto, RO Bonow (eds). 
Philadelphia, Elsevier Saunders, 2020, pp 267–288.
Otto CM et al: 2020 ACC/AHA guideline for the management of 
patients with valvular heart disease: A report of the American Col­
lege of Cardiology/American Heart Association Joint Committee on 
Clinical Practice Guidelines. Circulation 143:e72, 2021.
Yang L-T et al: Association of echocardiographic left ventricular endsystolic volume and volume-derived ejection fraction with outcome 
in asymptomatic chronic aortic regurgitation. JAMA Cardiol 6:189, 
2021.